Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Chiesi Farmaceutici S.p.A.
BioCentury | Oct 28, 2024
Deals
In $1.4B Aliada buy, AbbVie sees value in CNS delivery tech, as well as lead asset
Together, blood-brain barrier transport technology and Phase I Alzheimer’s therapy drive rare 10-figure early-stage takeout
BioCentury | Oct 17, 2024
Deals
More, faster deals, but smaller deals — Lazard co-heads of biopharma on this year’s M&A
Michael Kingston and Dale Raine on the capital markets and global deal-making landscape
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Mar 19, 2024
Product Development
Clinical report: Crinetics ready to advance oral acromegaly therapy to FDA
Plus: Phase IIb setback for Spruce, Inventiva combination in MASH, and more
BioCentury | Jan 23, 2024
Deals
Sanofi gets clinical AAT therapy via takeout-and-spinout deal with Inhibrx
Echoing Biohaven’s arrangement with Pfizer, most Inhibrx assets will land in a well-capitalized newco
BioCentury | Nov 10, 2023
Management Tracks
New CFO, CMO at TreeFrog
Plus: Metagenomi names Borges CSO and Wapnick CFO, and updates from Teva, Century, Assembly and more
BioCentury | Jul 7, 2023
Management Tracks
Zai promotes Chen to CFO
Plus: Chiesi elevates next generation, Lang now Lyell’s CBO and updates from OrbiMed, Gimv, Nkarta, InflaRx, Akamis and more
BioCentury | May 10, 2023
Deals
May 10 Quick Takes: Bicycle in third radiopharma deal of year
Plus: 15% weight reduction for Boehringer, Zealand Phase II asset and updates from Aviko, DiogenX, Syneos, OliX and more
BioCentury | May 5, 2023
Product Development
May 5 Quick Takes: Argenx’s Vyvgart tops 1Q23 consensus sales
Plus: Protalix/Chiesi therapy for Fabry wins EU approval, and updates from FibroGen, NGM and more
BioCentury | May 3, 2023
Data Byte
At least 18 PDUFA dates on FDA’s calendar for May
The decisions include Sarepta’s DMD candidate, which could become the first gene therapy to receive accelerated approval
Items per page:
1 - 10 of 186